{"groups":[{"description":"Dose escalation with rebastinib 50 milligram (mg) twice daily (BID) orally (PO) in 21-day cycles in combination with carboplatin administered by intravenous (IV) infusion at area under the curve (AUC)5 at Day 1 of each 21-day cycle.","id":"FG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"FG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"},{"description":"Dose expansion in triple-negative breast cancer (TNBC) participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG003","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG004","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG005","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG006","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG007","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"FG008","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"11"}],"comment":"Modified Intent-to-Treat (mITT) Population includes all participants who had at least one full dose of the combined study drugs, had measurable disease at baseline, and had at least one post-baseline assessment. Participants without a post-baseline assessment who discontinued study treatment due to clinical progression, death, or a rebastinib-related AE will also be included in the mITT population.","type":"mITT Population"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}